Display options
Cite
Gaig C, Compta Y, Heidbreder A, et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology. 2021;doi: 10.1212/WNL.0000000000012639.
Gaig, C., Compta, Y., Heidbreder, A., Marti, M. J., Titulaer, M. J., Crijnen, Y., Högl, B., Lewerenz, J., Erro, M. E., Garcia-Monco, J. C., Nigro, P., Tambasco, N., Patalong-Ogiewa, M., Erdler, M., Macher, S., Berger-Sieczkowski, E., Höftberger, R., Geis, C., Hutterer, M., Milán-Tomás, A., Martin-Bastida, A., Manzanares, L. L., Quintas, S., Höglinger, G. U., Möhn, N., Schoeberl, F., Thaler, F. S., Asioli, G. M., Provini, F., Plazzi, G., Berganzo, K., Blaabjerg, M., Brüggemann, N., Farias, T., Ng, C. F., Giordana, C., Herrero-San Martín, A., Huebra, L., Kotschet, K., Liendl, H., Montojo, T., Morata, C., Perez, J. P., Puertas, I., Seifert-Held, T., Seitz, C., Simabukuro, M. M., Tellez, N., Villacieros-Álvarez, J., Willekens, B., Sabater, L., Iranzo, A., Cano, J. S., Dalmau, J., & Graus, F. (2021). Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology, . https://doi.org/10.1212/WNL.0000000000012639
Gaig, Carles, et al. "Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease." Neurology vol. (2021). doi: https://doi.org/10.1212/WNL.0000000000012639
Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, Högl B, Lewerenz J, Erro ME, Garcia-Monco JC, Nigro P, Tambasco N, Patalong-Ogiewa M, Erdler M, Macher S, Berger-Sieczkowski E, Höftberger R, Geis C, Hutterer M, Milán-Tomás A, Martin-Bastida A, Manzanares LL, Quintas S, Höglinger GU, Möhn N, Schoeberl F, Thaler FS, Asioli GM, Provini F, Plazzi G, Berganzo K, Blaabjerg M, Brüggemann N, Farias T, Ng CF, Giordana C, Herrero-San Martín A, Huebra L, Kotschet K, Liendl H, Montojo T, Morata C, Perez JP, Puertas I, Seifert-Held T, Seitz C, Simabukuro MM, Tellez N, Villacieros-Álvarez J, Willekens B, Sabater L, Iranzo A, Cano JS, Dalmau J, Graus F. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology. 2021 Aug 11; doi: 10.1212/WNL.0000000000012639. Epub 2021 Aug 11. PMID: 34380749; PMCID: PMC8520389.
Copy Download .nbib Format: NLM
Share it on

Neurology. 2021 Aug 11; doi: 10.1212/WNL.0000000000012639. Epub 2021 Aug 11.

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.

Neurology

Carles Gaig, Yaroslau Compta, Anna Heidbreder, Maria J Marti, Maarten J Titulaer, Yvette Crijnen, Birgit Högl, Jan Lewerenz, María Elena Erro, Juan Carlos Garcia-Monco, Pasquale Nigro, Nicola Tambasco, Maja Patalong-Ogiewa, Marcus Erdler, Stefan Macher, Evelyn Berger-Sieczkowski, Romana Höftberger, Christian Geis, Markus Hutterer, Angela Milán-Tomás, Antonio Martin-Bastida, Lydia Lopez Manzanares, Sonia Quintas, Günter U Höglinger, Nora Möhn, Florian Schoeberl, Franziska S Thaler, Gian Maria Asioli, Federica Provini, Giuseppe Plazzi, Koldo Berganzo, Morten Blaabjerg, Norbert Brüggemann, Tarsis Farias, Chen Fei Ng, Caroline Giordana, Alejandro Herrero-San Martín, Lucio Huebra, Katya Kotschet, Herburg Liendl, Teresa Montojo, Carlos Morata, Jesus Perez Perez, Inmaculada Puertas, Thomas Seifert-Held, Caspar Seitz, Mateus Mistieri Simabukuro, Nieves Tellez, Javier Villacieros-Álvarez, Barbara Willekens, Lidia Sabater, Alex Iranzo, Joan Santamaria Cano, Josep Dalmau, Francesc Graus

Affiliations

  1. Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  2. Department of Neurology, Hospital Clinic, Barcelona, Spain.
  3. Multidisciplinary Sleep Disorders Unit, Hospital Clinic, Barcelona, Spain.
  4. Parkinson's disease & Movement Disorders Unit, Hospital Clinic, Barcelona, Spain.
  5. Department Neurology, Division of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Muenster, Germany.
  6. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  7. Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  8. Department of Neurology, Ulm University, Ulm, Germany.
  9. Neurology Department, Complejo Hospitalario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  10. Neurology Department. Hospital Universitario de Basurto. Bilbao. Spain (formerly Department of Neurology, Hospital de Galdakao, Spain).
  11. Movement Disorders Center, Perugia General Hospital and University of Perugia, Perugia, Italy.
  12. Department of Neurology and Neurorehabilitation. Faculty of Medical Sciences in Katowice. Medical University of Silesia, Katowice, Poland.
  13. Department of Neurology, Klinik Donaustadt, Karl-Landsteiner-Institut, Vienna, Austria.
  14. Department of Neurology, Medical University of Vienna, Austria.
  15. Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria.
  16. Section Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
  17. Department of Neurology 1, Neuromed Campus, Kepler Universitätsklinikum Linz, Linz, Austria. Department of Neurology with Stroke Unit and Acute Geriatrics, Saint John of God Hospital Linz, Linz, Austria.
  18. Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona-Madrid. Spain.
  19. Department of Neurology, Hospital La Princesa, Madrid, Spain.
  20. Department of Neurology, Hannover Medical School, Hannover, Germany.
  21. Department of Neurology, Ludwig-Maximilians-University; Munich, Germany.
  22. Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
  23. Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  24. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  25. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy.
  26. Neurology Department, Cruces University Hospital, Barakaldo, Spain.
  27. Department of Neurology, Odense University Hospital, Odense, Denmark.
  28. Department of Neurology and Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
  29. Department of Neurology, Medical Clinic of Hospital Geral Cleriston Andrade, Feira de Santana, Brazil.
  30. Neurology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
  31. Department of Movement Disorders and Neurology, CHU Nice, Nice, France.
  32. Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  33. Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.
  34. Clinical Neurosciences, St Vincent's Hospital, Melbourne, Australia.
  35. Department of Neurology, LKH Murtal, Standort Knittelfeld, Austria.
  36. Department of Neurology, Fundación Jiménez Diaz, Madrid, Spain.
  37. Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  38. Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  39. Department of Neurology, Hospital La Paz, Madrid, Spain.
  40. Department of Neurology, Medical Universtity of Graz, Graz, Austria.
  41. Department of Neurology, Mainz University Hospital, Mainz, Germany.
  42. Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil.
  43. Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain.
  44. Department of Neurology, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
  45. Department of Neurology, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
  46. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  47. Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain [email protected].

PMID: 34380749 PMCID: PMC8520389 DOI: 10.1212/WNL.0000000000012639

Abstract

OBJECTIVE: Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease.

METHODS: In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders.

RESULTS: Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases.

CONCLUSIONS: Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.

© 2021 American Academy of Neurology.

References

  1. Mov Disord. 2017 Jun;32(6):853-864 - PubMed
  2. Ann Neurol. 2020 Nov;88(5):1023-1027 - PubMed
  3. Neurology. 2017 May 2;88(18):1736-1743 - PubMed
  4. J Alzheimers Dis. 2017;59(1):13-20 - PubMed
  5. Brain. 2018 Jan 1;141(1):13-36 - PubMed
  6. Mov Disord. 2008 Nov 15;23(15):2129-70 - PubMed
  7. Mov Disord. 2013 Apr;28(4):543-7 - PubMed
  8. Neurology. 2018 Oct 23;91(17):e1659 - PubMed
  9. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e136 - PubMed
  10. Front Neurol. 2019 Oct 02;10:1056 - PubMed
  11. Neurol Neuroimmunol Neuroinflamm. 2019 May 21;6(4):e577 - PubMed
  12. Mov Disord. 1995 Mar;10(2):195-200 - PubMed
  13. Mov Disord. 2011 May;26(6):947-57 - PubMed
  14. Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2): - PubMed
  15. J Neurol. 2019 Apr;266(4):1031-1033 - PubMed
  16. Mov Disord Clin Pract. 2018 Nov 08;5(6):653-656 - PubMed
  17. Neurology. 2017 Oct 3;89(14):1471-1475 - PubMed
  18. Arch Neurol. 2010 Sep;67(9):1109-15 - PubMed
  19. J Neuroinflammation. 2016 Sep 01;13(1):226 - PubMed
  20. Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(6): - PubMed
  21. Neurology. 2013 Mar 19;80(12):1133-44 - PubMed
  22. Lancet Neurol. 2014 Jun;13(6):575-86 - PubMed
  23. J Neurol. 2020 Nov;267(11):3169-3176 - PubMed
  24. Front Neurol. 2018 May 17;9:329 - PubMed
  25. Mov Disord Clin Pract. 2020 May 05;7(5):557-559 - PubMed
  26. Neurology. 2004 Jul 13;63(1):66-72 - PubMed
  27. Mov Disord Clin Pract. 2021 Feb 25;8(3):460-463 - PubMed
  28. Neurol Neuroimmunol Neuroinflamm. 2015 Dec 10;3(1):e186 - PubMed
  29. Curr Opin Neurol. 2019 Jun;32(3):493-499 - PubMed
  30. Mov Disord. 2014 Dec;29(14):1758-66 - PubMed
  31. Mov Disord Clin Pract. 2016 Jul 28;4(3):441-443 - PubMed
  32. Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e385 - PubMed
  33. Lancet Neurol. 2017 Jul;16(7):552-563 - PubMed
  34. Mov Disord. 2015 Feb;30(2):171-9 - PubMed
  35. Neurology. 2018 Jun 12;90(24):1113-1115 - PubMed
  36. N Engl J Med. 2015 Jan 15;372(3):249-63 - PubMed
  37. J Neurol Sci. 2018 Feb 15;385:175-184 - PubMed
  38. Medicine (Baltimore). 2019 May;98(20):e15706 - PubMed
  39. Eur J Neurol. 2021 Apr;28(4):1392-1395 - PubMed
  40. J Neurol Neurosurg Psychiatry. 2017 May;88(5):412-417 - PubMed
  41. J Neuromuscul Dis. 2017;4(4):337-339 - PubMed
  42. Mov Disord Clin Pract. 2020 Sep 29;7(Suppl 3):S83-S84 - PubMed
  43. Mov Disord. 2016 May;31(5):762-4 - PubMed
  44. Neurology. 2018 Jul 24;91(4):180-182 - PubMed
  45. Nat Rev Neurol. 2018 Mar;14(3):183-189 - PubMed
  46. J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):724-726 - PubMed
  47. Neurology. 2021 Jun 8;96(23):e2901-e2902 - PubMed
  48. Lancet. 2015 Apr 18;385(9977):1590 - PubMed
  49. J Neuroimmunol. 2016 Nov 15;300:9-10 - PubMed
  50. J Neurol. 2011 Nov;258(11):2058-68 - PubMed

Publication Types